Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study

M.-A. Richard, J.-P. Lacour, M.-P. Konstantinou, M. Ruer-Mulard, P. Joly, S. Aractingi, P. Auquier, B. Pelvet, M.L. Augustin, E. Mahé, R.J.G. Chalmers

1Ceress-EA 3279, Research Centre in Health Services and Quality of Life Aix Marseille University, Marseille, France
2Department of Dermatology, University Hospital Timone Marseille, APHM, Marseille, France
3Department of Dermatology, University Hospital of Nice, Archet-2 Hospital, Nice, France
4Department of Dermatology, Larrey Hospital and Paul Sabatier University, Toulouse, France
5Private Office, Martigues, France
6Department of Dermatology, Rouen University Hospital, University of Rouen Normandie, Rouen, France
7Department of Dermatology, Cochin-Tarnier Hospital, Paris, France
8Department of Public Health, University Hospital Timone Marseille, APHM, Marseille, France
9R&D, Novartis Pharma SAS, Rueil-Malmaison, France
10Department of Dermatology, Victor Dupouy Hospital, Argenteuil, France
11Centre for Dermatology, University of Manchester, Manchester, UK

*Correspondence: M.-A. Richard. E-mail: mariealeth.richard@ap-hm.fr

Abstract

Background The utility of the Simplified Psoriasis Index (SPI), a recently developed multidomain tool for assessing psoriasis, was investigated in a study assessing response to secukinumab.

Methods In an open-label, multicentre study involving 17 French centres, patients with moderate-to-severe plaque psoriasis received secukinumab 300 mg subcutaneously once weekly from baseline to W4, then every 4 weeks until W48. Dermatologist-scored SPI psoriasis severity (proSPI-s) was compared with Psoriasis Area and Severity Index (PASI). Patient self-assessed severity (saSPI-s) and psychosocial impact (SPI-p) were compared with PASI and Dermatology Life Quality Index (DLQI), respectively.

Results We included 120 patients (69.2% male; mean age 45.9 years; mean duration of psoriasis 21.6 years). Mean baseline scores were as follows: proSPI-s 24.9, saSPI-s 23.5, PASI 23.1, SPI-p 8.2 and DLQI 13.6. Severity scores achieved by 16 weeks (proSPI-s 2.3, saSPI-s 2.2 and PASI 2.2) were maintained to W52. Reductions in mean psychosocial impact scores were maintained to W52 (SPI-p and DLQI, respectively, 2.1 and 1.5 at W16; 1.5 and 1.9 at W52).

Conclusions Decrease of PASI scores in response to secukinumab was closely correlated with proSPI-s, supporting the latter’s suitability for assessing response to therapy. Although the correlation between PASI and saSPI-s was slightly weaker, patients were able to complete a valid assessment of their psoriasis independently, and thus potentially remotely. With the added benefit of psychosocial impact assessment (SPI-p), SPI provides a valid tool enabling patients to assess their own psoriasis, remotely if necessary.

Received: 22 April 2020; Accepted: 9 July 2020

Conflicts of interest

M.-A. Richard has acted as a consultant for Abbvie, Amgen, Boehringer, Celgene, Lilly, Janssen Cilag, LEO Pharma, Pierre Fabre, Novartis, Pfizer, Sanofi/Regeneron, and UCB and served as an investigator for Abbvie, Boehringer, Galderma, Janssen Cilag, Leo Pharma, Lilly, Novartis, Pierre Fabre and Sanofi/Regeneron. J.-P. Lacour has acted as an investigator receiving grants from Abbvie, Amgen, BMS, Boehringer Ingelheim, Celgene, Galderma, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Regeneron and Roche; as a consultant receiving honoraria from Celgene, Galderma, LEO Pharma, Lilly, Novartis, Regeneron, Roche and Sanofi; and as a speaker receiving honoraria from Abbvie.

[Correction added on 29 October 2020, after first online publication: In the Abstract and Figure 4b label, ‘saSPI-p 8.2’ and ‘(b) saSPI-s’ have been corrected to ‘SPI-p 8.2’ and ‘(b) SPI-p’ respectively]
BMS, Celgene, Galderma, LEO Pharma, Lilly, Novartis, Roche and Sanofi. M.-P. Konstantinou has acted as an investigator for AbbVie, Amgen, BMS, Boehringer Ingelheim, Celgene, UCB, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Regeneron and Roche, and a speaker for Novartis, Lilly, Janssen and AbbVie. M. Ruer-Mulard has acted as an investigator for Novartis, Lilly, Janssen, LEO Pharma, AbbVie and Ave; as a consultant for Janssen and Sanofi; and as a speaker for Novartis, Lilly, Janssen and AbbVie. P. Joly has acted as a consultant for Novartis Lilly, Janssen and Celgene. E. Mahé has paid activities as a consultant, advisor or speaker for AbbVie, Boehringer-Ingelheim, Janssen, Celgene, LEO Pharma, Lilly, Amgen, AstraZeneca, Novartis and Pfizer. S. Aractingi has acted as a consultant for Novartis and a speaker receiving honoraria from Novartis and Lilly. B. Pelvet is an employee of Novartis Pharma. M. Augustin is an employee of Novartis Pharma. P. Auquier and R.J.G. Chalmers have no conflict of interest.

**Funding source**

NOVARTIS SAS.

---

**What’s already known about this topic?**

- The Psoriasis Area and Severity Index (PASI) is widely required by funding bodies for decisions on access to biologic therapy but has been repeatedly criticized.
- The Simplified Psoriasis Index (SPI) is a recently developed alternative psoriasis measurement tool which assesses both psoriasis severity and its psychosocial impact.
- Secukinumab has been shown to be an effective treatment for moderate-to-severe psoriasis.

**What does this study add?**

- Reductions in PASI scores were closely paralleled by those of the severity domain of SPI.
- Efficacy of secukinumab was demonstrated for each of the 10 body sites scored by SPI.
- The severity and psychosocial impact domains of proSPI correlated well with PASI and the Dermatology Life Quality Index, respectively.
- The good correlation between physicians’ (proSPI-s) and patients’ (saSPI-s) scores opens the possibility of using saSPI to monitor patients remotely.

**Introduction**

Chronic plaque psoriasis is an inflammatory immune-mediated disease manifesting as disfiguring scaly red patches on the skin, often accompanied by itching or soreness. It can have a profound impact on quality of life including a patient’s emotional, social, occupational and physical functioning. Although there is currently no cure for psoriasis, the disease may respond to a wide range of treatment strategies.

EudraCT number: 2014-003666-25 US NCT number: NCT02595970

Secukinumab, a monoclonal anti-IL-17A antibody, has been shown to be an effective treatment for moderate-to-severe psoriasis. Subcutaneous administration of 300 mg per week during the induction phase (first month) and 300 mg per month thereafter has proven to be the optimal regimen.

In recent years, most studies of interventions for psoriasis have used the Psoriasis Area and Severity Index (PASI) for assessing psoriasis severity and its response to treatment. Together with the Dermatology Life Quality Index (DLQI) for assessing changes in the functional and psychological impact of psoriasis with treatment. The PASI has well-known limitations, notably that it fails to take into account the added impact of psoriasis affecting functionally or psychosocially important body sites and how this may affect patients’ well-being. The DLQI, which is not psoriasis specific, contains a number of components which are irrelevant to many psoriasis patients, and the upper half of its range (16–30) is infrequently used.

The Simplified Psoriasis Index (SPI), recently developed in Britain, is a holistic psoriasis assessment instrument which incorporates separate domains for current severity (SPI-s), psychosocial impact (SPI-p) and past history and interventions (SPI-i), as shown in Fig. 1. It is available in complementary versions either for completion by healthcare professionals (proSPI) or for self-assessment by patients (saSPI); the only difference between the two is that technical language is avoided in the latter. The current severity domain (SPI-s) accords extra weight to certain functionally or psychosocially important body sites (scalp, face, anogenital area, hands, feet, with nail psoriasis contributing to scores for the latter two sites if appropriate). Good correlation between PASI and both versions of SPI-s and between DLQI and SPI-p was demonstrated in a study of 100 psoriasis patients using the original English version of SPI and, more recently, in a study using a version translated into Thai. A further study by the same investigators confirmed the responsiveness of SPI-s to change.

The current severity domain of SPI (SPI-s) consists of two components: psoriasis extent (part 1A) for which the extent of psoriasis involving 10 unequally sized body sites (Fig. 1) is...
scored on a 3-point scale: 0, absent or minimal; 0.5, ‘noticeable’; or 1, extensive, and overall average plaque severity (part 1B), which is scored on a scale of 0 (essentially clear) to 5 (intensely inflamed skin). SPI-s is the product of the scores for parts 1A (maximum 10) and 1B (maximum 5), giving a maximum current severity score of 50.

The psychosocial impact score (SPI-p) is marked by the patient on a 10 cm visual analogue scale and converted to an 11-point Likert scale from 0 (‘My psoriasis is not affecting me at all’) to 10 (‘My psoriasis is affecting me very much – I could not imagine it affecting me more’). The historical course and interventions score (SPI-i) is assessed by 10 questions, four relating to disease course and six to previous interventions received.12 It is not discussed further in this report. Both versions of SPI have recently been translated into French and linguistically validated using a well-established procedure (Figs S1 and S2, Supporting Information).13

The primary objective of the present study was to compare proSPI with PASI as a tool for assessing psoriasis severity in patients treated with secukinumab. Secondary objectives were to compare patient self-assessments (saSPI-s and SPI-p) with PASI and DLQI, respectively.

Methods

Diagnosis and main criteria for inclusion

Patients aged ≥18 were eligible for inclusion if they had had moderate-to-severe chronic plaque psoriasis for at least 6 months prior to the screening visit, were considered suitable for systemic therapy and met the following criteria at baseline: PASI ≥12, Body Surface Area (BSA) ≥10 and Investigator’s Global Assessment (IGA) modified 2011 ≥3. Furthermore, they were required to understand and communicate with the investigator and to be able to comply with the study protocol. The validated French translations of PASI, DLQI and SPI were used for the study.

The study protocol and all amendments were reviewed by the Independent Sud Mediterranée I Ethics Committee on 12 June 2012 (EudraCT 2014-003666-25). The study was carried out in accordance with the Helsinki declaration and good clinical
practices guidelines, and patients signed a written informed consent to participation in the study.

**Study design**
This was an open-label, multicentre, single-arm phase IIIb study conducted in 17 centres in France. The study consisted of a screening, a treatment, and a follow-up period. During the treatment period (W0–W48), patients received 300 mg of subcutaneous secukinumab (two injections of 150 mg) weekly until W4, and every 4 weeks thereafter. If at W16 the treatment was judged by the investigator to be beneficial for the patient, 4-weekly injections of 150 mg were initiated until W4, and every 4 weeks thereafter. If at W16 the treatment was judged by the investigator to be beneficial for the patient, 4-weekly injections were continued up to W48, either at the investigation site when attending a visit (W24, W32, W40 and W48) or at home between visits (W20, W28, W36 and W44). Patients were followed up to W52.

**Study objectives**
The primary objective was to investigate the response of moderate-to-severe plaque psoriasis to secukinumab at W16 as assessed independently by the dermatologist and by the patient using proSPI-s (professionally assessed current severity domain of SPI) and saSPI-s (patient self-assessed current severity domain of SPI), respectively.

Secondary objectives were as follows: (i) to evaluate the correlation between PASI and proSPI-s; (ii) to assess each domain of proSPI-s and saSPI-s and the DLQI over the full duration of the study; and (iii) to evaluate safety of secukinumab up to W52. Additional exploratory objectives were to evaluate the correlations between: (iv) saSPI-s and PASI; (v) proSPI-s and saSPI-s; and (vi) the psychosocial impact scores, SPI-p and DLQI.

**Efficacy and safety analyses**
Efficacy parameters were analysed on the full analysis set (FAS) population, which comprised all patients from the included population who were administered at least one dose of investigational drug with at least one baseline and one post-baseline SPI evaluation.

Efficacy of secukinumab was assessed by examining absolute and percentage changes from baseline of PASI and of DLQI at W16 and at W52. The proSPI-s and saSPI-s scores at the same time points were compared with each other and with PASI. SPI-p was compared with DLQI.

Safety of secukinumab was evaluated by the summary of treatment-emergent adverse events (AEs) including severity, study treatment-related AEs, serious adverse events (SAEs), AEs leading to study drug discontinuation, and AEs leading to death.

**Statistical analysis**
Continuous variables are presented as means (± standard deviation) and graphically as medians and interquartile ranges; categorical variables are presented as numbers of patients and percentages. Comparisons between the mean proSPI-s, saSPI-s and PASI between baseline and W16 were tested by the paired t-test after confirmation that the data sets were normally distributed. Correlation between scales (proSPI-s vs. PASI; SPI-p vs. DLQI; proSPI-s vs. saSPI-s) at each post-baseline visit was estimated using Spearman’s rank correlation coefficient. A p-value ≤0.05 was considered significant. Statistical analyses were performed using SAS version 9.4. (SAS Institute, Cary, NC, USA).

**Results**

**Demographic and disease characteristics**
Between 20 May 2015 and 06 Jan 2016, 137 patients were screened. Of them, 120 were entered into the study, 111 (92.5%) completed the initial 16-week induction treatment, and 100 (83.3%) continued treatment to W48.

Of the 120 patients (mean age ± SD: 45.9 ± 14.2 years), 111 (92.5%) were ≤65 years, 83 (69.2%) were male, and 116 (96.7%) were Caucasian. At the time of recruitment, patients had had psoriasis for a mean (±SD) of 21. ± (12.8) years; psoriasis involving significant body sites was recorded in the following proportion of cases: scalp 47.5%, nails 33.3%, and palmoplantar skin 19.2%. Patient and disease characteristics at baseline are presented in Table S1 (Supporting Information). All but one subject (119/120) had previously received systemic psoriasis treatment (including retinoids, methotrexate or ciclosporin) and/or phototherapy; 63/120 (52.5%) were naïve to biologic psoriasis therapy.

**Primary efficacy endpoint**
The FAS population comprised 119 patients. The mean (±SD) proSPI-s score in the FAS population decreased significantly from 24.9 (±10.8) at baseline to 2.3 (±6.1) at W16, which corresponded to an absolute change of 22.6 (P < 0.0001) and a relative change of −90.9% (Fig. 2). The mean (±SD) saSPI-s score at baseline was 23.5 (±10.4) and decreased to 2.0 (±4.5) by W16, which corresponded to a mean absolute change of −21.6 (P < 0.0001) and a relative change of −88.8% (Fig. 2).

**Secondary endpoints**
The mean (±SD) PASI score decreased from 23.0 (±10.5) at baseline to 2.2 (±3.9) at W16 (P < 0.0001) and 3.2 (±5.4) at W52. The correlation between proSPI-s and PASI was moderate at baseline (0.69) and strong from W2 (0.76) up to W52 (0.93). By W16, PASI-50 was achieved in 96.3% (105/109), PASI-75 in 85.3% (93/109), PASI-90 in 68.8% (75/109) and PASI-100 in 38.5% (42/109). At W52, PASI-50, PASI-75, PASI-90 and PASI-100 response rates were 93.5% (86/92), 83.7% (77/92), 65.2% (60/92) and 37.0% (34/92), respectively.

The decreases of mean proSPI-s and saSPI-s scores observed at W16 were maintained to W52 with absolute reductions of 22.2 (88.5%) and 21.8 (81.9%), respectively (Fig. 2).

Data from proSPI-s showed that psoriasis affecting functionally or psychosocially significant sites was extensive (extent...
Psoriasis Area and Severity Index (PASI), (b) professionally assessed Simpli...

Figure 2 Changes in mean and median psoriasis severity scores over the course of the study (full analysis set population, N = 119): (a) Psoriasis Area and Severity Index (PASI), (b) professionally assessed Simplified Psoriasis Index (SPI) current severity score (proSPI-s) and (c) patient self-assessed SPI current severity score (saSPI-s). Means are represented by diamonds; medians with interquartile and overall ranges are represented by box and whisker plots.

Figure 2

The safety population comprised 120 patients. At least one adverse event was documented in 13 (10.8%) patients, of which two (1.7%) experienced events that were considered by the supervising physician to be due to the study drug (stomatitis in one patient and punctate keratitis and Sjögren syndrome in the other). Five patients had an adverse event that led to discontinuation of secukinumab. Two patients died during the study but the causes of death (cranial trauma and cutaneous lymphoma) were not related to the study treatment.

Discussion

We present here the results from a clinical study designed to assess the utility of SPI for documenting response to secukinumab treatment in patients with moderate-to-severe plaque psoriasis using a validated translation of SPI into French.

The study has shown that the current severity domain of both versions of SPI (proSPI-s and saSPI-s) successfully demonstrated their ability to capture the progressive fall in psoriasis extent and severity in response to the introduction of secukinumab in patients with moderate-to-severe psoriasis. Major reductions in mean proSPI-s and saSPI-s scores were already apparent by W8 (Fig. 2) and reached 90.9% and 88.8%, respectively, at W16. These improvements were then maintained throughout the remainder of the study.

The study has demonstrated that the ability of proSPI-s to capture response to therapy is comparable to that achieved by PASI, with a strong correlation between the two instruments over time. This confirms that SPI is at least as reliable an instrument as PASI for assessing psoriasis severity. Furthermore, the fact that saSPI-s (patient self-assessed severity) is strongly correlated with proSPI-s (physician-assessed severity) indicates that patients and physicians have similar perceptions of psoriasis severity. This is an important point for managing patients in...
**Figure 3** proSPI-s scores at Week 0 and Week 16 for each of 10 body sites. Numbers of scores for each extent category: (1) widespread and involving much of the affected area; (0.5) obvious but still leaving plenty of normal skin and (0) clear or minimal with no more than a few scattered thin plaques.

**Figure 4** Changes in mean and median psychosocial impact scores over the course of the study (full analysis set population, \( N = 119 \)): (a) Dermatology Life Quality Index (DLQI) and (b) Simplified Psoriasis Index psychosocial impact score (SPI-p). Means are represented by diamonds; medians with interquartile, and overall ranges are represented by box and whisker plots.
Table 1  (a) Correlation analyses between PASI, proSPI-s and saSPI-s. (b) Correlation analyses between (i) psoriasis severity scores (PASI, proSPI-s and saSPI-s) and psychosocial impact scores (SPI-p and DLQI); and (ii) the two psychosocial impact scores

| (a) Spearman’s correlation coefficient (95% CI) | proSPI-s | saSPI-s |
|-----------------------------------------------|---------|---------|
| PASI                                           |         |         |
| Baseline                                      | 0.691 (0.58, 0.78) | 0.490 (0.34, 0.62) |
| W16                                           | 0.814 (0.74, 0.87) | 0.701 (0.59, 0.79) |
| W52                                           | 0.927 (0.89, 0.95) | 0.645 (0.51, 0.75) |

| Baseline                                      | 0.551 (0.41, 0.67) | 0.551 (0.41, 0.67) |
| W16                                           | 0.677 (0.56, 0.77) | 0.677 (0.56, 0.77) |
| W52                                           | 0.715 (0.60, 0.80) | 0.715 (0.60, 0.80) |

| (b) Spearman’s correlation coefficient (95% CI) | SPI-p | DLQI |
|-----------------------------------------------|-------|------|
| PASI                                           |       |      |
| Baseline                                      | 0.173 (–0.01, 0.34) | 0.497 (0.34, 0.62) |
| W16                                           | 0.678 (0.56, 0.77) | 0.585 (0.43, 0.71) |
| W52                                           | 0.749 (0.64, 0.83) | 0.694 (0.54, 0.82) |

| proSPI-s                                      |       |      |
| Baseline                                      | 0.224 (0.04, 0.39) | 0.224 (0.04, 0.39) |
| W16                                           | 0.418 (0.250, 0.56) | 0.418 (0.250, 0.56) |
| W52                                           | 0.514 (0.34, 0.65) | 0.514 (0.34, 0.65) |

| saSPI-s                                       |       |      |
| Baseline                                      | 0.480 (0.33, 0.61) | 0.480 (0.33, 0.61) |
| W16                                           | 0.666 (0.55, 0.76) | 0.666 (0.55, 0.76) |
| W52                                           | 0.716 (0.60, 0.80) | 0.716 (0.60, 0.80) |

| SPI-p                                        |       |      |
| Baseline                                      | 0.551 (0.41, 0.67) | 0.551 (0.41, 0.67) |
| W16                                           | 0.774 (0.69, 0.84) | 0.774 (0.69, 0.84) |
| W52                                           | 0.840 (0.77, 0.89) | 0.840 (0.77, 0.89) |

CI, confidence interval; DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index; proSPI-s, professionally assessed psoriasis severity score; saSPI-s, patient self-assessed psoriasis severity score; SPI-p, patient psychosocial impact score; W, week.

routine clinical practice where the SPI can be completed by the patient, saving the physician time and giving the patient some measure of ownership of their disease management.

The limitations of PASI for scoring psoriasis are well known. SPI has been designed to capture the additional functional and psychological impact of psoriasis involving certain body sites, which are also often difficult to treat: the scalp, face, hands and feet (including nails) and anogenital area account for up to 50% of the SPI extent score.15,16 SPI has the advantage over PASI of enabling response to treatment in each of its ten body sites to be assessed independently. The efficacy of secukinumab could be demonstrated by SPI-s in each of these sites, thus providing a more sophisticated assessment of treatment response than is possible with PASI. By way of example, scalp psoriasis was extensive (extent score = 1) in 44.5% of patients at baseline and in only 1.8% at W16, an improvement which was sustained to W52. Similar responses to secukinumab were observed for the anogenital, hands and feet locations, supporting previous secukinumab studies dedicated to specific psoriasis locations in which site-specific questionnaires were used (GESTURE NCT01806597, TRANSFIGURE NCT01807520 and SCALP NCT02267135).17–19

Based on the mean DLQI value at baseline, psoriasis had a very strong impact on patients’ quality of life (QoL). As observed in previous phase III studies, there was a marked decrease in mean DLQI scores in response to secukinumab, from 13.6 at baseline to 2.1 at W16 (83.5% reduction) and 1.9 at W52.2,20,21 These changes were paralleled by reductions in patients’ SPI psychosocial impact scores (SPI-p), which decreased from 8.2 at baseline to 1.3 at W16 (84.1% reduction) and 1.5 at W52. These similar responses were reflected in the strong correlation between SPI-p and DLQI over time. It should be noted, however, that the full range of SPI-p scores (0–10) was used whereas the top half of the range of DLQI (16–30) was little used.

Incorporation of a psychosocial impact assessment into an instrument for assessing psoriasis severity enhances its utility as a score for global assessment of the disease not only for clinical studies but also for daily clinical practice. An additional advantage of SPI lies in its ability to capture the burden and responsiveness of psoriasis affecting functionally or psychosocially important body sites that may disproportionately affect a patient’s QoL. The ability of patients to record the severity and impact of their psoriasis themselves using saSPI not only gives them some ownership of the management of their disease but also provides a means for physicians to be able to monitor response to treatment remotely.

The safety profile of secukinumab was consistent with that previously reported,2,20,21 and no new or unexpected signals were identified during the study. Discontinuation of therapy due to an adverse event occurred in 4.2% of patients. There were two deaths during the study that were deemed unrelated to study treatment.

Conclusions

The French version of SPI, the relevant domains of which (SPI-s and SPI-p) correlated well with PASI and DLQI, respectively, appears to provide a simple mean of assessing psoriasis severity, its psychosocial impact and the response of both to treatment. Furthermore, SPI enables the anatomical distribution of psoriasis and the differential responses to intervention in different body sites to be documented more clearly. SPI was found by...
dermatologists and patients alike to be straightforward to use and thus suitable for use both in clinical trials and in routine clinical practice.

Acknowledgements

Novartis Pharma SAS funded this study. We thank the following physicians who recruited and supervised patients: Dr Maud AMY DE LA BRETEQUE; Pr Sélim ARACTINGI; Dr Pierre-André BECHEREL; Pr Christophe BEDANE; Pr Marie BEYLLOT-BARRY; Dr Thierry BOYE; Dr Philippe CELERIER; Dr Guillaume CHABY; Dr Jean-François CUNY; Pr Vincent DESCAMPS; Pr Alain DUPUY; Dr Anne-Bénédicte DUVAL-MODESTE; Dr Eric ESTEVE; Pr Pascal JOLY; Dr Maria-Polina KONSTANTINOU; Pr Jean-Philippe LACOUR; Dr Emmanuel MAHE; Dr Hervé MAILLARD; Pr Laurent MISERY; Pr Carle PAUL; Pr Marie-Aleth RICHARD; and Dr Mireille RUERMULARD, and also all patients who participated to the study in France. We thank Jone Iriondo (ITEC Services) for medical writing and editorial assistance.

References

1. Lebwohl M, Swensen AR, Nyirady JP et al. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol 2014; 53: 714–722.
2. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 2014; 371: 326–338.
3. Blauvelt A, Prinz JC, Gottlieb AB et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015; 172: 484–493.
4. Paul C, Lacour J-P, Tedremets L et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 2015; 29: 1082–1090.
5. Thaci D, Blauvelt A, Reich K et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73: 405–409.
6. Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies. Clin Dermatol 2010; 28: 67–72.
7. Spuls PI, Lecluse LLA, Poulsen M-LNF et al. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol 2010; 130: 933–943.
8. Gourraud P-A, Le Gall C, Puzenet E et al. Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis. J Invest Dermatol 2012; 132: 2171–2175.
9. Ramsey B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991; 124: 565–570.
10. Chularojanamontri L, Griffiths CEM, Chalmers RJG. The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. J Invest Dermatol 2013; 133: 1956–1962.
11. Chularojanamontri L, Wonggraruprat C, Winaynuwattikun W et al. A reevaluation of the Simplified Psoriasis Index (SPI) using the thai language version: a study examining the validity, reliability, and interpretability of SPI when used in translation. J Psoriasis Psoriatic Arthritis 2020; 9: 32–39.
12. Chularojanamontri L, Griffiths CEM, Chalmers RJG. Responsiveness to change and interpretability of the simplified psoriasis index. J Invest Dermatol 2014; 134: 351–358.
13. Richard MA, Aractingi S, Joly P et al. French adaptation of a new score for global assessment of psoriasis severity: the Simplified Psoriasis Index (SPI). Ann Dermatol Venereol 2019; 146: 783–792.
14. Langley RGB, Feldman SR, Nyirady JP et al. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat 2015; 26: 23–31.
15. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol 2008; 26: 448–459.
16. van de Kerkhof PCM, Murphy GM, Austad J et al. Psoriasis of the face and flexures. J Dermatol Treat 2007; 18: 351–360.
17. Bagel J, Duffin KC, Moore A et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol 2017; 77: 667–674.
18. Reich K, Sullivan J, Arenberger P et al. Effect of secukinumab on clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol 2018; 181: 954–966. https://doi.org/10.1111/bjd.17351
19. Gottlieb A, Sullivan J, van Doorn M et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol 2017; 76: 70–80.
20. Blauvelt A, Reich K, Tsai T-F et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol 2017; 76: 60–69.e9.
21. Bissonnette R, Luger T, Thaçi D et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018; 32: 1507–1514.

Supporting information

Additional Supporting Information may be found in the online version of this article:

Figure S1. French version of proSPI.
Figure S2. French version of saSPI.
Table S1. Baseline demographic and disease characteristics of included patients.